This observation aligns with emerging evidence from pivotal clinical trials, where ICIs plus chemotherapy showed consistent benefit even in low PD-L1 expression patients, suggesting that immunotherapy efficacy may not be entirely dependent on PD-L1 expression levels in gastric cancer. The gene discussed is CD274; the disease is gastric cancer.